How does Calaspargase Pegol actually kill leukemia cells?
Calaspargase Pegol is an enzyme that breaks down asparagine, an amino acid that leukemia cells need to survive and divide. By depleting asparagine in the bloodstream, the drug starves cancer cells while normal cells can make their own asparagine [1].
The DFCI 11-001 trial (2021) showed that Calaspargase Pegol maintains asparagine depletion (keeping blood levels below 0.1 µmol/L) for 2 weeks between doses, matching the efficacy of older asparaginase drugs [1]. The pegylation—coating the enzyme with a long-chain polymer—makes it last longer in your bloodstream and triggers fewer allergic reactions [2].
Inside your body, Calaspargase Pegol circulates through your blood and breaks down asparagine molecules into aspartate and ammonia. Leukemia cells cannot make their own asparagine (they lack the enzyme asparagine synthetase), so they die when the drug depletes the supply [2]. Normal cells survive because they can synthesize asparagine from other amino acids.
The real-world trade-off is that Calaspargase Pegol can damage your pancreas (pancreatitis), liver, and blood clotting system if asparagine depletion is too aggressive [1]. Your oncologist monitors your amylase, liver enzymes, and PT/INR blood tests every 2 weeks to catch toxicity early and adjust dosing if needed [3].
Ask your oncologist: 'How often will you check my amylase and liver enzymes, and what symptoms should I report immediately?' Pancreatitis pain (upper belly, radiating to back) and unusual bruising are red flags that need same-day clinic contact [1].